Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States

Jia, X., Zhao, Y., Carrico, J., Brodtkorb, T-H., Mendelsohn, A., Lowry, S., Feldman, S., Wu, JJ., & Armstrong, A. (2018). Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States. Journal of managed care & specialty pharmacy, 24(10-a Suppl), S79. https://doi.org/10.18553/jmcp.2018.24.10-a.s1

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Internalizing and externalizing subtypes of alcohol misuse and their relation to drinking motives
Article

Does the relationship between alcohol retail environment and alcohol outcomes vary by depressive symptoms? Findings from a US Survey of Black, Hispanic and White drinkers
Article

What's in a name? A data-driven method to identify optimal psychotherapy classifications to advance treatment research on co-occurring PTSD and substance use disorders
Article

Grandi Byen-supporting child growth and development through integrated, responsive parenting, nutrition and hygiene